Dr. Teitelbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 convention Center Boulevard
South Tower 10
Philadelphia, PA 19104Phone+1 215-662-6319Fax+1 215-662-2432- Is this information wrong?
Summary
- Dr. Ursina Teitelbaum is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and UPMC Presbyterian. She received her medical degree from University of Maryland School of Medicine and has been in practice 18 years. She also speaks multiple languages, including German and French. She is experienced in medical oncology, palliative medicine and geriatrics. Her subspecialty is gastrointestinal oncology.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2003 - 2005
- University of ChicagoFellowship, Geriatric Medicine (Internal Medicine), 2002 - 2003
- University of ChicagoResidency, Internal Medicine, 1999 - 2002
- University of Maryland School of MedicineClass of 1999
Certifications & Licensure
- PA State Medical License 2006 - 2024
- IL State Medical License 1999 - 2008
Awards, Honors, & Recognition
- Deenie Greitzer and Daniel G Haller Associate Professorship University of Pennsylvania, 2015-2016
- Academy of Master Clinicians University of Pennsylvania, 2014-2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 1 citationsIntegrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.Soulen, M., Teitelbaum, U., Mick, R., Eads, J., Mondschein, J., Dagli, M., van Houten, D., Damjanov, N., Schneider, C., Cengel, K., Metz, D.> ;Cardiovascular and Interventional Radiology. 2024 Jan 1
- The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.Arielle Yablonovitch, Jacob E Till, Jennifer Yen, Lesli A Kiedrowski, Ryan Hood, Mark H O'Hara, Ursina Teitelbaum, Erica L Carpenter, Katherine Nathanson, Susan M Domc...> ;Clinical Cancer Research. 2023 Dec 15
- 35 citationsNiraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.Kim A Reiss, Rosemarie Mick, Ursina Teitelbaum, Mark O'Hara, Charles Schneider, Ryan Massa, Thomas Karasic, Rashmi Tondon, Chioma Onyiah, Mary Kate Gosselin, Alyssa Do...> ;The Lancet. Oncology. 2022 Aug 1
- Join now to see all
Press Mentions
- For Alex Trebek, the Toughest Question: Can He Face down Pancreatic Cancer?March 7th, 2019
- Alex Trebek Has Stage 4 Pancreatic Cancer. Here's What That MeansMarch 7th, 2019
- The Future of Pancreatic Cancer: A Conversation with Medical Oncologist Mark O'Hara, MDFebruary 11th, 2019
- Join now to see all
Other Languages
- German, French
Hospital Affiliations
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
- Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: